Compile Data Set for Download or QSAR
maximum 50k data
Found 4675 of Enz. Inhib. data with enzyme = 'Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform' and Substrate = 'to-be-curated'
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0790nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0790nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM295675(US10851091, U.S. Pat. No. 8,242,104 No. 469 | US82...)
Affinity DataKi:  0.390nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50149477(CHEMBL3770993 | US10851091, U.S. Pat. No. 8,242,10...)
Affinity DataKi:  0.417nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM295687(US10851091, U.S. Pat. No. 8,263,633 No. 356 | US82...)
Affinity DataKi:  0.920nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295679(US10851091, U.S. Pat. No. 8,242,104 No. 529 | US82...)
Affinity DataKi:  1.05nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  1.43nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM25028(4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpipera...)
Affinity DataKi:  1.54nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
LigandPNGBDBM475622(US10851091, U.S. Pat. No. 8,242,104 No. 549 isomer...)
Affinity DataKi:  1.70nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295686(US10851091, U.S. Pat. No. 8,242,104 No. 550 | US82...)
Affinity DataKi:  1.96nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295676(US10851091, U.S. Pat. No. 8,242,104 No. 486 | US82...)
Affinity DataKi:  2.5nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50149548(CHEMBL3771364 | US10851091, U.S. Pat. No. 8,242,10...)
Affinity DataKi:  6.94nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM475621(US10851091, U.S. Pat. No. 8,242,104 No. 549 isomer...)
Affinity DataKi:  9.41nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295684(US10851091, U.S. Pat. No. 8,242,104 No. 544 | US82...)
Affinity DataKi:  11.3nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295665((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  12.2nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  16.7nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295671((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  17.5nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  17.8nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295665((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  18.2nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM295677(US10851091, U.S. Pat. No. 8,242,104 No. 501 | US82...)
Affinity DataKi:  21.8nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295671((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  23.7nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295682(US10851091, U.S. Pat. No. 8,242,104 No. 540 | US82...)
Affinity DataKi:  24.1nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295669((S)-2-cyclopropyl-2-((2-((S)-4- (fluoromethyl)-2-o...)
Affinity DataKi:  30.3nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295669((S)-2-cyclopropyl-2-((2-((S)-4- (fluoromethyl)-2-o...)
Affinity DataKi:  36.4nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM475607(US10851091, Compound 103)
Affinity DataKi:  37.7nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM25028(4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpipera...)
Affinity DataKi:  41.8nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
LigandPNGBDBM295667((S)-2-cyclopropyl-2-((2-((S)-4- (difluoromethyl)-2...)
Affinity DataKi:  49nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295668((S)-2-cyclopropyl-2-((2-((R)-4- methyl-2-oxooxazol...)
Affinity DataKi:  197nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295666((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...)
Affinity DataKi:  286nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295668((S)-2-cyclopropyl-2-((2-((R)-4- methyl-2-oxooxazol...)
Affinity DataKi:  289nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295666((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...)
Affinity DataKi:  708nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326278(US9637488, 54)
Affinity DataIC50: <0.0500nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326285(US9637488, 68)
Affinity DataIC50: <0.0500nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326282(US9637488, 65)
Affinity DataIC50: <0.0500nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326284(US9637488, 67)
Affinity DataIC50: <0.0500nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326286(US9637488, 69)
Affinity DataIC50: <0.0500nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326267(US9637488, 27)
Affinity DataIC50: <0.0500nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326259(US9637488, 18)
Affinity DataIC50:  0.100nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM474011(N-(5-{2-[(1S)-1-Cyclopropylethyl]-7-({[1-(fluorome...)
Affinity DataIC50:  0.398nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM474007(N-(5-{2-[(1S)-1-Cyclopropylethyl]-7-(ethylsulfamoy...)
Affinity DataIC50:  0.398nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM326262(US9637488, 22 | US9637488, 24)
Affinity DataIC50:  0.5nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM474028(N-(5-{7-[(3-Cyanophenyl)sulfamoyl]-2-[(1S)-1-cyclo...)
Affinity DataIC50:  0.501nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM474015(N-(5-{2-[(1S)-1-Cyclopropylethyl]-7-[(cyclopropyls...)
Affinity DataIC50:  0.631nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM474012(N-(5-{2-[(1S)-1-Cyclopropylethyl]-1-oxo-7-[(2,2,2-...)
Affinity DataIC50:  0.631nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM474008(N-(5-{2-[(1S)-1-Cyclopropylethyl]-7-(oxetan-3-ylsu...)
Affinity DataIC50:  0.631nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50274648(CHEMBL4127396 | US10858355, Example 22)
Affinity DataIC50:  0.631nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM50274638(CHEMBL4126156 | US10858355, Example 4)
Affinity DataIC50:  0.631nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM326261(US9637488, 21)
Affinity DataIC50:  0.700nMAssay Description:Exemplary compounds of the invention were tested their inhibitory activity or potency against PI3Kδ in 10-dose IC50 mode with 3-fold serial dilu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM474017(N-(5-{2-[(1S)-1-Cyclopropylethyl]-7-[(ethylsulfony...)
Affinity DataIC50:  0.794nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50274648(CHEMBL4127396 | US10858355, Example 22)
Affinity DataIC50:  0.794nMAssay Description:The activity of recombinant human PI3Kγ (aa144-1102)-6His was determined by measuring the ADP level after phosphorylation of DiC8-PIP2 using a c...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 4675 total ) | Next | Last >>
Jump to: